Abselion’s CEO, Dr. Ruizhi Wang, was recently featured in a BioCompare editorial article, “Cell-Based Gene Therapies: Challenges and Advances in Upstream Manufacturing.”
The piece brings together perspectives from leaders across the field, highlighting the hurdles and opportunities in developing scalable, robust upstream processes for cell-based gene therapies.
Alongside contributors from MaxCyte, Elegen, CTMC, and BioSpherix, Dr. Wang shared insights on the importance of reliable protein quantification and process monitoring in advancing these complex therapies.